Companies Cidara Therapeutics, Inc.
Cidara Therapeutics CEO salary & total pay, FY2024: $6M
Cidara Therapeutics (CDAR) CEO salary, fiscal 2024: Jeffrey Stein was paid a salary of $617,600 and $5,965,903 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Cidara Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Jeffrey Stein's complete compensation dossier
A PDF and a CSV sent to your email: Jeffrey Stein's pay in every fiscal year Cidara Therapeutics, Inc. reported it, line by line, with Jeffrey Stein's equity grants and Cidara Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,558,544FY2023
- $5,965,903FY2024
CEO total pay was $5,965,903 in fiscal 2024, up from $1,558,544 in fiscal 2023.
FY2024: salary $617,600 · bonus $0 · stock awards $0 · option awards $4,867,353
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeffrey Stein | $617,600 | $0 | $0 | $4,867,353 | $470,600 | $0 | $10,350 | $5,965,903 |
| President and Chief Executive Officer | ||||||||
| Leslie Tari | 453,500 | 0 | 76,188 | 1,276,166 | 224,200 | 0 | 10,350 | 2,040,404 |
| Chief Scientific Officer | ||||||||
| Taylor Sandison | 505,100 | — | 88,174 | 1,411,601 | 0 | — | 10,350 | 2,015,225 |
| Former Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Jeffrey Stein | $5,965,903 | $1,558,544 | — | ↑ +4,407,359 |
| Leslie Tari | 2,040,404 | — | — | — |
| Taylor Sandison | 2,015,225 | 884,092 | — | ↑ +1,131,133 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our compensation program is designed to encourage our management team to achieve our short-term and long-term corporate objectives while effectively managing business risks and challenges. We provide a competitive total compensation package through a combination of base salary, an annual performance-based bonus, and long-term equity-based incentives to align the interests of our employees with those of our stockholders.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon Consulting, Inc. |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Jeffrey Stein | Option | 15,124 | 1,375 | 16.65 | — |
| Jeffrey Stein | RSU | — | 2,723 | — | 73,194 |
| Jeffrey Stein | Option | 15,855 | 11,319 | 20.2 | — |
| Jeffrey Stein | RSU | — | 9,058 | — | 243,479 |
| Jeffrey Stein | Option | 13,005 | 38,994 | 13.7 | — |
| Jeffrey Stein | Option | 46,741 | 514,147 | 10.75 | — |
| Jeffrey Stein | Option | 10,274 | — | 137.2 | — |
| Jeffrey Stein | Option | 7,949 | — | 197.8 | — |
| Jeffrey Stein | Option | 11,000 | — | 156 | — |
| Jeffrey Stein | Option | 11,749 | — | 80 | — |
| Jeffrey Stein | Option | 13,249 | — | 52.2 | — |
| Jeffrey Stein | Option | 16,499 | — | 39.6 | — |
| Jeffrey Stein | Option | 26,249 | — | 51 | — |
| Leslie Tari | Option | 4,814 | 435 | 16.65 | — |
| Leslie Tari | RSU | — | 867 | — | 23,305 |
| Leslie Tari | Option | 5,255 | 3,744 | 20.2 | — |
| Leslie Tari | RSU | — | 3,000 | — | 80,640 |
| Leslie Tari | Option | 2,786 | 8,338 | 13.7 | — |
| Leslie Tari | RSU | — | 5,562 | — | 149,507 |
| Leslie Tari | Option | 12,519 | 137,705 | 10.75 | — |
| Leslie Tari | Option | 3,696 | — | 49 | — |
| Leslie Tari | Option | 2,746 | — | 49 | — |
| Leslie Tari | Option | 4,249 | — | 39.6 | — |
| Leslie Tari | Option | 5,999 | — | 51 | — |
| Leslie Tari | Option | 1,499 | — | 30.4 | — |
| Taylor Sandison | Option | 4,585 | 414 | 16.65 | — |
| Taylor Sandison | RSU | — | 825 | — | 22,176 |
| Taylor Sandison | Option | 5,250 | 3,750 | 20.2 | — |
| Taylor Sandison | RSU | — | 3,000 | — | 80,640 |
| Taylor Sandison | Option | 2,950 | 8,824 | 13.7 | — |
| Taylor Sandison | RSU | — | 6,437 | — | 173,027 |
| Taylor Sandison | Option | 13,903 | 152,933 | 10.75 | — |
| Taylor Sandison | Option | 3,499 | — | 80 | — |
| Taylor Sandison | Option | 3,249 | — | 52.2 | — |
| Taylor Sandison | Option | 3,094 | — | 49 | — |
| Taylor Sandison | Option | 202 | — | 49 | — |
| Taylor Sandison | Option | 7,249 | — | 39.6 | — |
| Taylor Sandison | Option | 7,249 | — | 51 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel BurgessIndependent · Audit (Chair) · Nominating and Governance | $92,000 | — | $359,511 | — | — | $451,511 |
| Theodore R. SchroederIndependent · Audit · Compensation and Human Capital (Chair) | 64,000 | — | 359,511 | — | — | 423,511 |
| Chrysa MineoIndependent · Audit · Compensation and Human Capital | 56,500 | — | 334,604 | — | — | 391,104 |
| Carin Canale-TheakstonIndependent · Compensation and Human Capital | 47,500 | — | 284,789 | — | — | 332,289 |
| Bonnie BasslerIndependent · Nominating and Governance (Chair) | 46,767 | — | 284,789 | — | — | 331,556 |
| James MersonIndependent · Nominating and Governance | 30,189 | — | 58,073 | — | — | 88,262 |
| Ryan SpencerIndependent | 27,444 | — | 58,073 | — | — | 85,517 |
| Laura TadvalkarIndependent | 27,444 | — | 58,073 | — | — | 85,517 |
| Timothy R. FransonIndependent | 17,113 | — | 0 | — | — | 17,113 |
| David GollaherIndependent | 13,567 | — | 0 | — | — | 13,567 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $422,524 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $422,524 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Cidara Therapeutics as a peer
Companies that benchmark against CDAR
1 company names CDAR as a compensation peer
- SELLAS Life Sciences Group, Inc.SLSFY2025
Each company listed discloses CDAR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDAR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Cidara Therapeutics, Inc. | 2024 | Jeffrey Stein | $617,600 | $0 | $4,867,353 | $470,600 | $5,965,903 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-18 | 8,077,470 | 2,745,374 | 10,577 | 74.56% | Passed |
| 2024 | 2024-07-18 | 2,174,835 | 155,452 | 13,439 | 93.33% | Passed |
| 2023 | 2023-06-22 | 25,902,449 | 798,488 | 204,039 | 96.27% | Passed |
| 2022 | 2022-06-22 | 22,246,854 | 4,142,811 | 216,629 | 83.62% | Passed |
| 2021 | 2021-06-23 | 24,880,078 | 454,234 | 365,375 | 96.81% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-18 | 74.56%a |
| 2024 | 2024-07-18 | 93.33%b |
| 2023 | 2023-06-22 | 96.27%c |
a. Approved under the standard stated in the filing — “• To be approved, Proposal 6, the advisory approval of the compensation of our named executive officers, must receive "For" votes from the holders of a majority of shares present by virtual attendance at the Annual Meeting or represented by proxy and entitled to vote on the matter at the virtual Annual Meeting. || Abstentions: Abstentions will have the same effect as "Against" votes.”.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as "Against" votes.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Nicole Negar Davarpanah | Chief Medical Officer | 2025-05-01 | A | 20,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2025-05-01 | A | 10,000 | 0 | 0 | Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2025-06-02 | A | 2,270 | 22 | 49,281 | Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2025-06-03 | A | 1,050 | 23 | 24,614 | Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Merson | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2025-06-18 | A | 11,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joshua Resnick | Director | 2025-06-18 | A | 5,079 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-06-18 | A | 5,079 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2025-06-26 | A | 2,272,727 | 44 | 99,999,988 | Common, indirect | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2025-09-11 | D | 474 | 63 | 29,797 | Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2025-12-10 | D | 10,332 | 220 | 2,268,907 | Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | D | 6,459 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | D | 3,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | D | 9,959 | 220 | 2,191,747 | Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | A | 6,459 | 20 | 130,472 | Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | A | 3,500 | 17 | 58,289 | Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2025-12-10 | D | 15,041 | 220 | 3,303,004 | Common | Form 4 ↗ |
| Frank Karbe | Chief Financial Officer | 2025-12-10 | D | 7,290 | 220 | 1,600,884 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-10 | D | 2,285 | 220 | 501,786 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-10 | A | 33,072 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-10 | D | 33,072 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-17 | A | 2,244 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-17 | D | 2,244 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-19 | A | 10,638 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-19 | D | 10,638 | 0 | 0 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2025-12-22 | D | 5,425 | 0 | 0 | Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2025-12-29 | D | 450 | 0 | 0 | Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 20,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 30,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 62,597 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 5,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 8,333 | — | — | Common | Form 4 ↗ |
| Nicole Negar Davarpanah | Chief Medical Officer | 2026-01-07 | D | 12,553 | 222 | 2,780,490 | Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 50,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 135,540 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 12,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 6,207 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 12,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Shane Ward | COO & CLO | 2026-01-07 | D | 25,083 | 222 | 5,555,885 | Common | Form 4 ↗ |
| Frank Karbe | Chief Financial Officer | 2026-01-07 | D | 115,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Frank Karbe | Chief Financial Officer | 2026-01-07 | D | 43,125 | — | — | Common | Form 4 ↗ |
| Frank Karbe | Chief Financial Officer | 2026-01-07 | D | 7,526 | 222 | 1,667,009 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 275,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 560,888 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 51,999 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 27,174 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 16,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 26,249 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 16,499 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 13,249 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 11,749 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 11,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 7,949 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 67,498 | 222 | 14,950,807 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 2,379 | 222 | 526,949 | Common | Form 4 ↗ |
| Jeffrey Stein | Director | 2026-01-07 | D | 5,763 | 222 | 1,276,505 | Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 20,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 1,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Daniel Burgess | Director | 2026-01-07 | D | 150 | 222 | 33,225 | Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 20,500 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 1,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Theodore R. Schroeder | Director | 2026-01-07 | D | 450 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 19,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 1,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 550 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 1,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Chrysa Mineo | Director | 2026-01-07 | D | 3,320 | 222 | 735,380 | Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 1,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 1,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Bonnie Bassler | Director | 2026-01-07 | D | 15 | 222 | 3,323 | Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 16,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 1,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Carin Canale-Theakston | Director | 2026-01-07 | D | 1,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Merson | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Merson | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Merson | Director | 2026-01-07 | D | 4,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-01-07 | D | 11,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-01-07 | D | 2,125 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Ryan Spencer | Director | 2026-01-07 | D | 4,250 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joshua Resnick | Director | 2026-01-07 | D | 5,079 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Joshua Resnick | Director | 2026-01-07 | D | 22,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | D | 89,956 | 15,505 | 1,394,767,780 | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | D | 1,286,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | D | 5,079 | — | — | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | D | 22,200 | — | — | Derivative, Class A Common | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | D | 4,652,309 | 222 | 1,030,486,444 | Common, indirect | Form 4 ↗ |
| RA CAPITAL MANAGEMENT, L.P. | Director | 2026-01-07 | A | 1,286,786 | 0 | 129 | Common, indirect | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (144 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jeffrey Stein. DEF 14A, filed 2025-04-25. Section “Executive Compensation” · page 35. As printed: 5,965,903. View filing ↗
- Section 01, Leslie Tari. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 2,040,404. View filing ↗
- Section 01, Taylor Sandison. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 2,015,225. View filing ↗
- Section 08, Daniel Burgess. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 451,511. View filing ↗
- Section 08, Theodore R. Schroeder. DEF 14A. Section “Director Compensation”. As printed: 423,511.
- Section 08, Chrysa Mineo. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 391,104. View filing ↗
- Section 08, Carin Canale-Theakston. DEF 14A. Section “Director Compensation”. As printed: 332,289.
- Section 08, Bonnie Bassler. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 331,556. View filing ↗
- Section 08, James Merson. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 88,262. View filing ↗
- Section 08, Ryan Spencer. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 85,517. View filing ↗
- Section 08, Laura Tadvalkar. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 85,517. View filing ↗
- Section 08, Timothy R. Franson. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 17,113. View filing ↗
- Section 08, David Gollaher. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 13,567. View filing ↗
- Section 02, Nicole Negar Davarpanah 2025-05-01. Form 4, filed 2025-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2025-05-01. Form 4, filed 2025-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2025-06-02. Form 4, filed 2025-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2025-06-03. Form 4, filed 2025-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Merson 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Resnick 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-06-26. Form 4, filed 2025-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2025-09-11. Form 4, filed 2025-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Karbe 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-17. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-17. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-19. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-19. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2025-12-22. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2025-12-29. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Resnick 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joshua Resnick 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 74.56% (votes for as printed: 8,077,470). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-07-18. Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 2,174,835). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 96.27% (votes for as printed: 25,902,449). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 422,524 + equity 0 + all other 0 = 422,524, summed across the director compensation table rows.
- Cidara Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Cidara Therapeutics, Inc.'s own proxy. As printed: 5,965,903. View filing ↗